Correction: Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer

• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.614458/fu llWrong content There was a mistake in Figure 1 and Figure 2 as published. In Figure 1E, the Western blot image for GAPDH was incorrectly uploaded. In Figure 2B and 2C, the mistake caused by an unintentional assembly mistake. In Figure 2B, an inadvertent image duplication occurred between the CON and DOX groups in the CALDOX cell line. In Figure 2C, it has come to our attention that the data presented were inadvertently taken from a different experimental replicate. The corrected Figure 1 The original version of this article has been updated.Reminder: Figures, tables, and images will be published under a Creative Commons CC-BY license and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.